Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 463

1.

A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.

Lv C, Ma Y, Wu N, Yan S, Zheng Q, Sun Y, Li S, Fang J, Yang Y.

World J Surg Oncol. 2013 Mar 21;11:76. doi: 10.1186/1477-7819-11-76.

2.

Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.

Liao WY, Chen JH, Wu M, Shih JY, Chen KY, Ho CC, Yang JC, Yu CJ.

Clin Lung Cancer. 2013 Jul;14(4):418-24. doi: 10.1016/j.cllc.2012.10.003. Epub 2013 Jan 4.

PMID:
23291258
3.

Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.

Paramanathan A, Solomon B, Collins M, Franco M, Kofoed S, Francis H, Ball D, Mileshkin L.

Clin Lung Cancer. 2013 Sep;14(5):508-12. doi: 10.1016/j.cllc.2013.03.007. Epub 2013 Jun 20.

PMID:
23792009
4.

A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).

Schallier D, Neyns B, Fontaine C, Steene JV, De Mey J, Meysman M, De Grève J.

Lung Cancer. 2007 May;56(2):247-54. Epub 2007 Mar 6.

PMID:
17337086
5.

Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.

Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L.

Clin Lung Cancer. 2013 Jul;14(4):433-9. doi: 10.1016/j.cllc.2013.01.004. Epub 2013 Mar 22.

PMID:
23522953
6.

A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.

Treat J, Edelman MJ, Belani CP, Socinski MA, Monberg MJ, Chen R, Obasaju CK; Alpha Oncology Research Network.

Lung Cancer. 2010 Dec;70(3):340-6. doi: 10.1016/j.lungcan.2010.02.011. Epub 2010 Mar 27.

PMID:
20347506
7.

Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.

Sonett JR, Suntharalingam M, Edelman MJ, Patel AB, Gamliel Z, Doyle A, Hausner P, Krasna M.

Ann Thorac Surg. 2004 Oct;78(4):1200-5; discussion 1206. Review.

PMID:
15464470
8.

A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer.

Banna GL, Lipari H, Nicolosi M, Basile A, Fraggetta F, Vaglica M, Marletta F, Urso OE, Ippolito M, Terminella A, Saita S.

Med Oncol. 2013 Jun;30(2):533. doi: 10.1007/s12032-013-0533-8. Epub 2013 Mar 20.

PMID:
23512427
9.

Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.

Kosmas C, Tsavaris N, Vadiaka M, Stavroyianni N, Koutras A, Malamos N, Onyenadum A, Rokana S, Polyzos A, Kalofonos HP.

Cancer. 2001 Dec 1;92(11):2902-10.

PMID:
11753965
10.

Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.

Hirsh V, Soulieres D, Duclos M, Faria S, Del Vecchio P, Ofiara L, Ayoub JP, Charpentier D, Gruber J, Portelance L, Souhami L.

J Thorac Oncol. 2007 Oct;2(10):927-32.

11.

Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.

Natukula K, Jamil K, Pingali UR, Suresh Attili VS, Naidu Madireddy UR.

Asian Pac J Cancer Prev. 2013;14(8):4661-6.

12.
13.

Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced non-small cell lung cancer.

Beniwal SK, Patel KM, Shukla S, Parikh BJ, Shah S, Patel A.

Indian J Cancer. 2012 Apr-Jun;49(2):202-8. doi: 10.4103/0019-509X.102861.

14.

A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.

Lv C, Ma Y, Feng Q, Fang F, Bai H, Zhao B, Yan S, Wu N, Zheng Q, Li S, Chen J, Wang J, Feng Y, Wang Y, Pei Y, Fang J, Yang Y.

World J Surg Oncol. 2013 Apr 26;11:96. doi: 10.1186/1477-7819-11-96.

15.
16.

Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.

Garrido P, González-Larriba JL, Insa A, Provencio M, Torres A, Isla D, Sanchez JM, Cardenal F, Domine M, Barcelo JR, Tarrazona V, Varela A, Aguilo R, Astudillo J, Muguruza I, Artal A, Hernando-Trancho F, Massuti B, Sanchez-Ronco M, Rosell R.

J Clin Oncol. 2007 Oct 20;25(30):4736-42.

PMID:
17947721
17.
18.

Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).

Iranzo V, Sirera R, Carrato A, Cabrera A, Jantus E, Guijarro R, Sanmartín E, Blasco A, Gil M, Gómez-Aldaraví L, González-Larriba JL, Massuti B, Velasco A, Provencio M, Rossell R, Camps C.

Clin Transl Oncol. 2011 Jun;13(6):411-8.

PMID:
21680302
19.

Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.

Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, Stephenson J, Ung Y, Sanborn R, Pressnail B, Nugent F, Nemunaitis J, Gleave ME, Murray N, Hao D.

J Thorac Oncol. 2012 Mar;7(3):579-86. doi: 10.1097/JTO.0b013e31823f459c.

20.

Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.

Luo J, Leaw SJ, Xu Y, Zheng D.

Med Oncol. 2011 Dec;28(4):1418-24. doi: 10.1007/s12032-010-9575-3. Epub 2010 Jul 27.

PMID:
20661668

Supplemental Content

Support Center